Treatment of Cutaneous Larva Migrans with albendazole: preliminary report

Twenty three patients with Cutaneous Larva Migrans syndrome were prospectively treated with 400 mg/day of Albendazole for 3 consecutive days. Clinical response, compliance and tolerance was excellent. Patients were asymptomatic within the first 72 hours of treatment and recurrences did not occurred....

Full description

Bibliographic Details
Published in:Revista do Instituto de Medicina Tropical de São Paulo
Main Authors: Jaime R. Torres R., Angel R. Orihuela, David Garcia, Salha Abdul-Hadi
Format: Article in Journal/Newspaper
Language:English
Published: Universidade de São Paulo (USP) 1989
Subjects:
Cutaneous larva migrans
Treatment
Albendazole
Arctic medicine. Tropical medicine
RC955-962
Infectious and parasitic diseases
RC109-216
Arctic
Online Access:https://doi.org/10.1590/S0036-46651989000100012
https://doaj.org/article/94011fab07db4f3ba5ba81e4cd05c2fb
Description
Summary:Twenty three patients with Cutaneous Larva Migrans syndrome were prospectively treated with 400 mg/day of Albendazole for 3 consecutive days. Clinical response, compliance and tolerance was excellent. Patients were asymptomatic within the first 72 hours of treatment and recurrences did not occurred. Preliminary results with three additional patients suggest that a single oral 400 mg dose may be effective as well.

Similar Items